PALaDIN Study: High vs. Low Dose Iron in Peritoneal Dialysis Patients
Can high-dose iron improve health for people on peritoneal dialysis?
The PALaDIN study, a phase 3 trial, is recruiting to compare high-dose and low-dose iron treatments in peritoneal dialysis patients with ana…
People on peritoneal dialysis in the UK may see better health and fewer blood transfusions if they receive high-dose iron instead of low-dos…
Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria
Could a New Drug Offer Hope for Kidney Disease Sufferers?
A Phase 2 trial is evaluating ManNAc for primary FSGS in 30 patients. Primary endpoints include proteinuria reduction and safety. Results pe…
A new drug called ManNAc may help reduce protein loss in urine for people with kidney scarring, offering hope for those facing dialysis or t…
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
Could New Treatments Help Those Struggling with Kidney Disease?
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the per…
New kidney treatments aim to reduce urine protein and improve daily life for patients with FSGS or minimal change disease.